- What is molnupiravir used to treat?
- How do I get molnupiravir?
- What are the risks of molnupiravir?
- Is it safe to take molnupiravir while breastfeeding?
- When should I take molnupiravir?
- What is molnupiravir (lagevrio)?
- Does molnupiravir interact with other medications or foods?
- Can children take molnupiravir or nirmatrelvir?
What is molnupiravir used to treat?
Molnupiravir is the oral prodrug of beta-D-N4-hydroxycytidine (NHC), a ribonucleoside that has broad antiviral activity against RNA viruses. NHC uptake by viral RNA-dependent RNA-polymerases results in viral mutations and lethal mutagenesis. 1,2
How do I get molnupiravir?
Molnupiravir is only available on prescription. However, you will only be eligible to have the medicine either: through a national study where half of participants will be given the medicine If you are in the high risk group you may be sent a letter and a PCR test that you can do at home should you develop symptoms of COVID-19.
What are the risks of molnupiravir?
As molnupiravir causes viral RNA to mutate, there are concerns that it might cause mutations in host cells, as well. One study in animal cell cultures found mutations in cells treated with molnupiravir. This has led to worries that the drug might cause cancers or birth abnormalities.
Is it safe to take molnupiravir while breastfeeding?
Breastfeeding is not recommended during treatment with molnupiravir and for 4 days after your last dose. If you are breastfeeding or plan to breastfeed, talk to your healthcare provider about your options and specific situation before taking this medicine. are taking any medicines (prescription, over-the-counter, vitamins, or herbal products).
When should I take molnupiravir?
Molnupiravir comes as capsules. Youll need to start taking the capsules as soon as possible after you have tested positive for COVID-19 and within 5 days of your symptoms starting. If you are eligible for COVID-19 treatment you will usually be offered neutralising monoclonal antibodies (nMAbs), such as sotrovimab (Xevudy), before molnupiravir.
What is molnupiravir (lagevrio)?
Molnupiravir (Lagevrio, MK-4482, EIDD-2801) is Mercks antiviral capsule that has been used successfully in studies to treat mild to moderate COVID-19, reducing risk of hospitalization and death.
Does molnupiravir interact with other medications or foods?
According to the EUA, no drug-drug interactions have been identified for molnupiravir. MOVe-OUT was a multinational, Phase 3 trial that evaluated the use of molnupiravir in nonhospitalized adults with mild to moderate COVID-19 who were at high risk of progressing to severe COVID-19.
Can children take molnupiravir or nirmatrelvir?
Paxlovid (nirmatrelvir / ritonavir) can be used in children ages 12 and older, but molnupiravir can only be used in adults ages 18 and older because of possible bone and cartilage damage in people who are younger.
What are the side effects of molnupiravir?
Molnupiravir is not authorized for use in children aged <18 years due to potential effects on bone and cartilage growth. The most common adverse effects of molnupiravir are diarrhea, nausea, and dizziness.
Is molnupiravir a mutagenic antiviral?
Molnupiravir has potent antiviral activity against SARS-CoV-2. 1,5 As a mutagenic ribonucleoside antiviral agent, there is a theoretical risk that molnupiravir will be metabolized by the human host cell and incorporated into the host DNA, leading to mutations. Molnupiravir has been evaluated in 2 in vivo rodent mutagenicity assays.
Can I take molnupiravir If I am pregnant?
Molnupiravir isnt recommended in pregnancy. Currently, there arent enough studies done to understand how this medication affects human pregnancy, but animal studies show that it can cause birth defects. Because of this risk, your provider might ask you to take a pregnancy test before you start this medication.